N-(4-octylphenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine | 1163260-46-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并嘧啶类
• 英文名称: N-(4-octylphenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
• 英文别名: DSM119；5-methyl-N-(4-octylphenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
• CAS: 1163260-46-5
• 化学式: C₂₀H₂₇N₅
• 分子量: 337.468
• InChiKey: NNUQBILDUXPUIR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  25
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  7-羟基-5-甲基-1,3,4-三氮吲哚利嗪 在 三氯氧磷 作用下， 以 乙醇 为溶剂， 反应 0.75h， 生成 N-(4-octylphenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
  参考文献：
  名称：

  Lead Optimization of Aryl and Aralkyl Amine-Based Triazolopyrimidine Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase with Antimalarial Activity in Mice

  摘要：

  Malaria is one of the leading causes of severe infectious disease worldwide; yet, our ability to maintain effective therapy to combat the illness is continually challenged by the emergence of drug resistance. We previously reported identification of a new class of triazolopyrimidine-based Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors with antimalarial activity, leading to the discovery of a new lead series and novel target for drug development. Active compounds from the series contained a triazolopyrimidine ring attached to an aromatic group through a bridging nitrogen atom. Herein, we describe systematic efforts to optimize the aromatic functionality with the goal of improving potency and in vivo properties of compounds from the series. These studies led to the identification of two new substituted aniline moieties (4-SF(5)-Ph and 3,5-Di-F-4-CF(3)-Ph), which, when coupled to the triazolopyrimidine ring, showed good plasma exposure and better efficacy in the Plasmodium berghei mouse model of the disease than previously reported compounds from the series.

  DOI：

  10.1021/jm200265b

文献信息

• DIHYDROOROTATE DEHYDROGENASE INHIBITORS WITH SELECTIVE ANTI-MALARIAL ACTIVITY
  申请人：PHILLIPS Margaret

  公开号：US20090209557A1

  公开（公告）日：2009-08-20

  Compounds according to Formula I, Formula II, Formula III, Formula V, Formula VI, or to Formula VII, and pharmaceutical compositions of compounds that conform to Formula IV or Formula VIII: where R 1 through R 33 are prescribed, selectively inhibit P. falciparum dihydroorotate dehydrogenase. Accordingly, a method for preventing and treating malaria attaches to such compounds, as well as to pharmaceutically acceptable salts, solvates, stereoisomers, tautomers, and prodrugs thereof.

  按照公式I，公式II，公式III，公式V，公式VI或公式VII制备的化合物和符合公式IV或公式VIII的化合物的制药组合物：其中R1到R33被规定，可以选择性地抑制P. falciparum脱氢鞘氨酸脱氢酶。因此，一种预防和治疗疟疾的方法涉及到这些化合物，以及其药学上可接受的盐，溶剂化合物，立体异构体，互变异构体和前药。
• US9216983B2
  申请人：——

  公开号：US9216983B2

  公开（公告）日：2015-12-22
• Lead Optimization of Aryl and Aralkyl Amine-Based Triazolopyrimidine Inhibitors of <i>Plasmodium falciparum</i> Dihydroorotate Dehydrogenase with Antimalarial Activity in Mice
  作者：Ramesh Gujjar、Farah El Mazouni、Karen L. White、John White、Sharon Creason、David M. Shackleford、Xiaoyi Deng、William N. Charman、Ian Bathurst、Jeremy Burrows、David M. Floyd、David Matthews、Frederick S. Buckner、Susan A. Charman、Margaret A. Phillips、Pradipsinh K. Rathod

  DOI：10.1021/jm200265b

  日期：2011.6.9

  Malaria is one of the leading causes of severe infectious disease worldwide; yet, our ability to maintain effective therapy to combat the illness is continually challenged by the emergence of drug resistance. We previously reported identification of a new class of triazolopyrimidine-based Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors with antimalarial activity, leading to the discovery of a new lead series and novel target for drug development. Active compounds from the series contained a triazolopyrimidine ring attached to an aromatic group through a bridging nitrogen atom. Herein, we describe systematic efforts to optimize the aromatic functionality with the goal of improving potency and in vivo properties of compounds from the series. These studies led to the identification of two new substituted aniline moieties (4-SF(5)-Ph and 3,5-Di-F-4-CF(3)-Ph), which, when coupled to the triazolopyrimidine ring, showed good plasma exposure and better efficacy in the Plasmodium berghei mouse model of the disease than previously reported compounds from the series.